On September 28, 2010, the American Conference Institute hosted its FDA Boot Camp in Boston. Chad Landmon, Chair of the FDA Practice Group at Axinn, Veltrop & Harkrider LLP, gave a presentation focusing on bioequivalence issues and their impact on FDA approval of generic products. A copy of Chad's presentation can be viewed here: